Cargando…
Oral Metronidazole Desensitization for Immunoglobulin E (IgE)-Mediated Hypersensitivity
Low efficacy has been reported for the treatment of Trichomonas vaginalis with antimicrobial agents other than the 5-nitroimidazole class. Patients with immunoglobulin E (IgE)-mediated hypersensitivity reactions to drugs in this class, including metronidazole and tinidazole, may benefit from a desen...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375180/ https://www.ncbi.nlm.nih.gov/pubmed/35974856 http://dx.doi.org/10.7759/cureus.26849 |
_version_ | 1784767908785684480 |
---|---|
author | Hollis, Chantae C Mlauzi, Chamunorwa Ashton, Michael |
author_facet | Hollis, Chantae C Mlauzi, Chamunorwa Ashton, Michael |
author_sort | Hollis, Chantae C |
collection | PubMed |
description | Low efficacy has been reported for the treatment of Trichomonas vaginalis with antimicrobial agents other than the 5-nitroimidazole class. Patients with immunoglobulin E (IgE)-mediated hypersensitivity reactions to drugs in this class, including metronidazole and tinidazole, may benefit from a desensitization treatment. We present two patients with past medical histories of IgE-mediated hypersensitivity reactions to metronidazole who were successfully treated with metronidazole using a modified protocol. The first patient was a 39-year-old female diagnosed with trichomoniasis who had a previous reaction to metronidazole characterized by urticaria and pruritus. The second patient was a 53-year-old female who had a history of untreated trichomoniasis due to a previous anaphylactic reaction to metronidazole. Both patients were successfully treated in the intensive care unit (ICU) without signs and symptoms of the reaction. Physicians may use a desensitization protocol for patients with a presumed IgE-mediated hypersensitivity when only the 5-nitroimidazole class is efficacious for the treatment of trichomoniasis. |
format | Online Article Text |
id | pubmed-9375180 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-93751802022-08-15 Oral Metronidazole Desensitization for Immunoglobulin E (IgE)-Mediated Hypersensitivity Hollis, Chantae C Mlauzi, Chamunorwa Ashton, Michael Cureus Internal Medicine Low efficacy has been reported for the treatment of Trichomonas vaginalis with antimicrobial agents other than the 5-nitroimidazole class. Patients with immunoglobulin E (IgE)-mediated hypersensitivity reactions to drugs in this class, including metronidazole and tinidazole, may benefit from a desensitization treatment. We present two patients with past medical histories of IgE-mediated hypersensitivity reactions to metronidazole who were successfully treated with metronidazole using a modified protocol. The first patient was a 39-year-old female diagnosed with trichomoniasis who had a previous reaction to metronidazole characterized by urticaria and pruritus. The second patient was a 53-year-old female who had a history of untreated trichomoniasis due to a previous anaphylactic reaction to metronidazole. Both patients were successfully treated in the intensive care unit (ICU) without signs and symptoms of the reaction. Physicians may use a desensitization protocol for patients with a presumed IgE-mediated hypersensitivity when only the 5-nitroimidazole class is efficacious for the treatment of trichomoniasis. Cureus 2022-07-14 /pmc/articles/PMC9375180/ /pubmed/35974856 http://dx.doi.org/10.7759/cureus.26849 Text en Copyright © 2022, Hollis et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Internal Medicine Hollis, Chantae C Mlauzi, Chamunorwa Ashton, Michael Oral Metronidazole Desensitization for Immunoglobulin E (IgE)-Mediated Hypersensitivity |
title | Oral Metronidazole Desensitization for Immunoglobulin E (IgE)-Mediated Hypersensitivity |
title_full | Oral Metronidazole Desensitization for Immunoglobulin E (IgE)-Mediated Hypersensitivity |
title_fullStr | Oral Metronidazole Desensitization for Immunoglobulin E (IgE)-Mediated Hypersensitivity |
title_full_unstemmed | Oral Metronidazole Desensitization for Immunoglobulin E (IgE)-Mediated Hypersensitivity |
title_short | Oral Metronidazole Desensitization for Immunoglobulin E (IgE)-Mediated Hypersensitivity |
title_sort | oral metronidazole desensitization for immunoglobulin e (ige)-mediated hypersensitivity |
topic | Internal Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375180/ https://www.ncbi.nlm.nih.gov/pubmed/35974856 http://dx.doi.org/10.7759/cureus.26849 |
work_keys_str_mv | AT hollischantaec oralmetronidazoledesensitizationforimmunoglobulineigemediatedhypersensitivity AT mlauzichamunorwa oralmetronidazoledesensitizationforimmunoglobulineigemediatedhypersensitivity AT ashtonmichael oralmetronidazoledesensitizationforimmunoglobulineigemediatedhypersensitivity |